Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [¹⁷⁷Lu]Ludotadipep in Patients With Metastatic Castration-Resistant Prostate Cancer.

"availability of data and material the datasets generated or analyzed during the study are available from the corresponding author on reasonable request. supplement the supplement is available with this article at https://doi"

"Conflicts of Interest: Chansoo Park is an employee of FutureChem Co., Ltd., and Dae Yoon Chi is its chief executive officer. Seunggyun Ha has consultant agreement with FutureChem. Joo Hyun O has consultant agreements with FutureChem and Novartis, and as a member of the editorial board of the Korean Journal of Radiology, she was not involved in the editorial evaluation or decision to publish this article. All remaining authors have declared no conflicts of interest."

"Funding acquisition: Seunggyun Ha, Joo Hyun O, Chansoo Park, Dae Yoon Chi, Ji Youl Lee. Funding Statement: This research was supported by National Research Foundation of Korea (grant numbers: 2022R1A2C1009770, 2022R1I1A1A01069887). The phase I trial from which the data is derived was supported by FutureChem Co., Ltd."